Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome. (KESK-FIQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04938713

Recruitment Status : Recruiting

First Posted : June 24, 2021

Last Update Posted : August 27, 2021

See Contacts and Locations

Sponsor:

Collaborator:

Centre Hospitalier Universitaire de Liege

Information provided by (Responsible Party):

Brice Constant, MD, Centre Hospitalier Universitaire de Charleroi

Study Description

Brief Summary:

Ketamine and Esketamine intravenous perfusions can modulate chronic pain. The purpose of this study is to determine if Ketamine or Esketamine are favorable for outpatients suffering from fibromyalgia.

Condition or disease	Intervention/treatment	Phase
Fibromyalgia	Drug: Ketamine 50 MG/ML Drug: Esketamine 25 MG/ML	Not Applicable

Detailed Description:

Ketamine and Esketamine intravenous perfusions in Pain Clinic can modulate chronic pain and are therefore part of the therapeutic arsenal of the Anesthesiologist in pain management. Patients with fibromyalgia syndrome have elevated levels of glutamate in the brain. This is demonstrated by functional brain imaging techniques. Elevation of glutamate is demonstrated in the posterior insular cortex, positively correlating with lower pain thresholds which is a hallmark of fibromyalgia syndrome. Ketamine has (e.a.) an inhibitory role of the N-methyl-D-aspartate (NMDA) receptor: it is a non-competitive antagonist of the NMDA receptor. In this context, Esketamine is available recently. This is the levorotatory form of Ketamine.

The main objective of this study is to measure if there is a difference between Ketamine and Esketamine on patients with fibromyalgia syndrome via the fibromyalgia impact questionnaire (FIQ) and measurement of side effects after intravenous perfusion. The fibromyalgia impact questionnaire is a global assessment of symptoms: pain, function, fatigue, stiffness, discomfort when walking up stairs, difficulties at work, anxiety, depression, days not worked and days of good quality in the past week.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	50 participants
Allocation:	Randomized
Intervention Model:	Crossover Assignment
Masking:	Triple (Participant, Care Provider, Investigator)
Primary Purpose:	Treatment
Official Title:	Comparison of Ketamine and Esketamine in Ambulatory Patients Treated for Fibromyalgia Syndrome in Pain Clinic. A Single-center, Prospective, Randomized, Double-blind, Crossover Study.
Actual Study Start Date :	July 1, 2021
Estimated Primary Completion Date :	May 1, 2022
Estimated Study Completion Date :	September 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Fibromyalgia

MedlinePlus related topics: Fibromyalgia

Drug Information available for: Ketamine Esketamine

Genetic and Rare Diseases Information Center resources: Chronic Graft Versus Host Disease

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: AB group If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The AB sequence consists of patients starting with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour. The patient will receive a total of two infusions of Ketamine and two infusions of Esketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A "wash-out" period of one week will be observed between the two administration periods to avoid so-called "carry-over" effects according to which the administration of the first drug could influence the effect of the second drug administered.	Drug: Ketamine 50 MG/ML Intravenous Ketalar® 0,30 mg/kg in 1 hour. Drug: Esketamine 25 MG/ML Intravenous Vesierra® 0,15mg/kg in 1 hour.
BA group If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The BA sequence consists of patients starting with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour. The patient will receive a total of two infusions of Esketamine and then two infusions of Ketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A "wash-out" period of one week will be observed between the two administration periods to avoid so-called "carry-over" effects according to which the administration of the first drug could influence the effect of the second drug administered.	Drug: Ketamine 50 MG/ML Intravenous Ketalar® 0,30 mg/kg in 1 hour. Drug: Esketamine 25 MG/ML Intravenous Vesierra® 0,15mg/kg in 1 hour.

Arm

Intervention/treatment

Active Comparator: AB group

If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The AB sequence consists of patients starting with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.

The patient will receive a total of two infusions of Ketamine and two infusions of Esketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A "wash-out" period of one week will be observed between the two administration periods to avoid so-called "carry-over" effects according to which the administration of the first drug could influence the effect of the second drug administered.

Drug: Ketamine 50 MG/ML

Intravenous Ketalar® 0,30 mg/kg in 1 hour.

Drug: Esketamine 25 MG/ML

Intravenous Vesierra® 0,15mg/kg in 1 hour.

BA group

If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The BA sequence consists of patients starting with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.

The patient will receive a total of two infusions of Esketamine and then two infusions of Ketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A "wash-out" period of one week will be observed between the two administration periods to avoid so-called "carry-over" effects according to which the administration of the first drug could influence the effect of the second drug administered.

Drug: Ketamine 50 MG/ML

Intravenous Ketalar® 0,30 mg/kg in 1 hour.

Drug: Esketamine 25 MG/ML

Intravenous Vesierra® 0,15mg/kg in 1 hour.

Outcome Measures

Primary Outcome Measures :

Score variations of Fibromyalgia Impact Questionnaire [ Time Frame: At day 0 before starting each intravenous perfusion. ]
Fibromyalgia Impact Questionnaire (FIQ) completed by the patient. The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week. The score is between 0 and 100. In the severity analysis a FIQ total score from 0 to < 39 was found to represent a mild effect, ≥ 39 to < 59 a moderate effect, and ≥ 59 to 100 a severe effect.
Score variations of Fibromyalgia Impact Questionnaire [ Time Frame: At day 7 after each intravenous perfusion. ]
Fibromyalgia Impact Questionnaire (FIQ) completed by the patient. The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week. The score is between 0 and 100. In the severity analysis a FIQ total score from 0 to < 39 was found to represent a mild effect, ≥ 39 to < 59 a moderate effect, and ≥ 59 to 100 a severe effect.
Score variations of Fibromyalgia Impact Questionnaire [ Time Frame: At day 14 after each intravenous perfusion. ]
Fibromyalgia Impact Questionnaire (FIQ) completed by the patient. The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week. The score is between 0 and 100. In the severity analysis a FIQ total score from 0 to < 39 was found to represent a mild effect, ≥ 39 to < 59 a moderate effect, and ≥ 59 to 100 a severe effect.
Score variations of Fibromyalgia Impact Questionnaire [ Time Frame: At day 21 after each intravenous perfusion. ]
Fibromyalgia Impact Questionnaire (FIQ) completed by the patient. The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week. The score is between 0 and 100. In the severity analysis a FIQ total score from 0 to < 39 was found to represent a mild effect, ≥ 39 to < 59 a moderate effect, and ≥ 59 to 100 a severe effect.
Score variations of Fibromyalgia Impact Questionnaire [ Time Frame: At day 28 after each intravenous perfusion. ]
Fibromyalgia Impact Questionnaire (FIQ) completed by the patient. The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week. The score is between 0 and 100. In the severity analysis a FIQ total score from 0 to < 39 was found to represent a mild effect, ≥ 39 to < 59 a moderate effect, and ≥ 59 to 100 a severe effect.

Secondary Outcome Measures :

Heart rate disturbances after intravenous perfusion of Ketamine or Esketamine [ Time Frame: At the beginning (minute zero) of each intravenous perfusion. ]
Measurement of heart rate in Pain clinic during intravenous perfusion. Measurement in beat per minute.
Heart rate disturbances after intravenous perfusion of Ketamine or Esketamine [ Time Frame: After 30 minutes of each intravenous perfusion. ]
Measurement of heart rate in Pain clinic during intravenous perfusion. Measurement in beat per minute.
Heart rate disturbances after intravenous perfusion of Ketamine or Esketamine [ Time Frame: After 60 minutes of each intravenous perfusion. ]
Measurement of heart rate in Pain clinic during intravenous perfusion. Measurement in beat per minute.
Heart rate disturbances after intravenous perfusion of Ketamine or Esketamine [ Time Frame: After 90 minutes of each intravenous perfusion. ]
Measurement of heart rate in Pain clinic during intravenous perfusion. Measurement in beat per minute.
Heart rate disturbances after intravenous perfusion of Ketamine or Esketamine [ Time Frame: After 120 minutes of each intravenous perfusion. ]
Measurement of heart rate in Pain clinic during intravenous perfusion. Measurement in beat per minute.
Variations of Visual Analogue Scale for pain. [ Time Frame: At the beginning (minute zero) of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for pain. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.
Variations of Visual Analogue Scale for pain. [ Time Frame: After 30 minutes of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for pain. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.
Variations of Visual Analogue Scale for pain. [ Time Frame: After 60 minutes of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for pain. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.
Variations of Visual Analogue Scale for pain. [ Time Frame: After 90 minutes of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for pain. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.
Variations of Visual Analogue Scale for pain. [ Time Frame: After 120 minutes of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for pain. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.
Variations of Visual Analogue Scale for nausea. [ Time Frame: At the beginning (minute zero) of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for nausea. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no nausea" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater nausea.
Variations of Visual Analogue Scale for nausea. [ Time Frame: After 30 minutes of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for nausea. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no nausea" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater nausea.
Variations of Visual Analogue Scale for nausea. [ Time Frame: After 60 minutes of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for nausea. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no nausea" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater nausea.
Variations of Visual Analogue Scale for nausea. [ Time Frame: After 90 minutes of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for nausea. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no nausea" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater nausea.
Variations of Visual Analogue Scale for nausea. [ Time Frame: After 120 minutes of each intravenous perfusion. ]
Measurement of Visual Analogue Scale (VAS) for nausea. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no nausea" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater nausea.
Variations of non-invasive blood pressure. [ Time Frame: At the beginning (minute zero) of each intravenous perfusion. ]
Measurement of variations of systolic and diastolic non-invasive blood pressure with upper arm cuff. Measurement in mmHg.
Variations of non-invasive blood pressure. [ Time Frame: After 30 minutes of each intravenous perfusion. ]
Measurement of variations of systolic and diastolic non-invasive blood pressure with upper arm cuff. Measurement in mmHg.
Variations of non-invasive blood pressure. [ Time Frame: After 60 minutes of each intravenous perfusion. ]
Measurement of variations of systolic and diastolic non-invasive blood pressure with upper arm cuff. Measurement in mmHg.
Variations of non-invasive blood pressure. [ Time Frame: After 90 minutes of each intravenous perfusion. ]
Measurement of variations of systolic and diastolic non-invasive blood pressure with upper arm cuff. Measurement in mmHg.
Variations of non-invasive blood pressure. [ Time Frame: After 120 minutes of each intravenous perfusion. ]
Measurement of variations of systolic and diastolic non-invasive blood pressure with upper arm cuff. Measurement in mmHg.
Variations of pulse Oxygen saturation. [ Time Frame: At the beginning (minute zero) of each intravenous perfusion. ]
Measurement of variations of pulse Oxygen saturation (SpO2). Pulse oximetry is a non-invasive measures of oxygen saturation level in %. A normal SpO2 is typically between 95 and 100 percent. A SpO2 < 95 percent is considered low.
Variations of pulse Oxygen saturation. [ Time Frame: After 30 minutes of each intravenous perfusion. ]
Measurement of variations of pulse Oxygen saturation (SpO2). Pulse oximetry is a non-invasive measures of oxygen saturation level in %. A normal SpO2 is typically between 95 and 100 percent. A SpO2 < 95 percent is considered low.
Variations of pulse Oxygen saturation. [ Time Frame: After 60 minutes of each intravenous perfusion. ]
Measurement of variations of pulse Oxygen saturation (SpO2). Pulse oximetry is a non-invasive measures of oxygen saturation level in %. A normal SpO2 is typically between 95 and 100 percent. A SpO2 < 95 percent is considered low.
Variations of pulse Oxygen saturation. [ Time Frame: After 90 minutes of each intravenous perfusion. ]
Measurement of variations of pulse Oxygen saturation (SpO2). Pulse oximetry is a non-invasive measures of oxygen saturation level in %. A normal SpO2 is typically between 95 and 100 percent. A SpO2 < 95 percent is considered low.
Variations of pulse Oxygen saturation. [ Time Frame: After 120 minutes of each intravenous perfusion. ]
Measurement of variations of pulse Oxygen saturation (SpO2). Pulse oximetry is a non-invasive measures of oxygen saturation level in %. A normal SpO2 is typically between 95 and 100 percent. A SpO2 < 95 percent is considered low.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male and female
Between 18 and 75 years old
Reads and writes French
Diagnosis of fibromyalgia syndrome according to Widespread Pain Index (WPI) and Symptom Severity Scale (SSS) score ≥ 13/31
Both molecules (Ketamine and Esketamine) were administered at least once during an analgesic infusion session in Pain Clinic
Patient with regular medical follow-up by a pain specialist at least 3 times a year

Exclusion Criteria:

Allergy or intolerance to Ketamine or Esketamine
Current infection, fever
Pregnant or breastfeeding woman
Serious cardiovascular disorders and severe hypertension
Increased pressure of cerebrospinal fluid and severe intracranial disease
Acute intermittent porphyria
Untreated epilepsy
Untreated glaucoma
Difficult or impossible intravenous access
Chronic Liver Disease Child-Pugh C

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04938713

Contacts

Layout table for location contacts

Contact: Brice Constant, MD	0032477504934	briceconstant@hotmail.com
Contact: Romain Dehavay, MD	0032476684876	romain.dehavay@gmail.com

Locations

Layout table for location information

Belgium
CHU de Charleroi	Recruiting
Lodelinsart, Hainaut, Belgium, 6042
Contact: Brice JD Constant, MD 0032477504934 briceconstant@hotmail.com
Contact: Romain Dehavay, MD 0032476684876 romain.dehavay@gmail.com

Sponsors and Collaborators

Centre Hospitalier Universitaire de Charleroi

Centre Hospitalier Universitaire de Liege

Investigators

Layout table for investigator information

Principal Investigator:	Brice Constant, MD	Centre Universitaire de Charleroi

More Information

Layout table for additonal information

Responsible Party:	Brice Constant, MD, MD, Centre Hospitalier Universitaire de Charleroi
ClinicalTrials.gov Identifier:	NCT04938713
Other Study ID Numbers:	KESK-FIQ
First Posted:	June 24, 2021 Key Record Dates
Last Update Posted:	August 27, 2021
Last Verified:	August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No
Plan Description:	IPD will be available according to reasonable demands.

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No
Product Manufactured in and Exported from the U.S.:	No

Keywords provided by Brice Constant, MD, Centre Hospitalier Universitaire de Charleroi:


Fibromyalgia Ketamine Esketamine	Fibromyalgia Impact Questionnaire Side effects Chronic pain

Additional relevant MeSH terms:

Layout table for MeSH terms

Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases Ketamine Esketamine Analgesics Sensory System Agents Peripheral Nervous System Agents	Physiological Effects of Drugs Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antidepressive Agents Psychotropic Drugs

To Top